Opinion|Videos|February 21, 2025
Future Outlook in COPD
Panelists discuss how chronic obstructive pulmonary disease (COPD) management is evolving with personalized therapies, nonpharmacological care, and advanced treatments. Early diagnosis, adherence, and innovation offer hope for improved outcomes and quality of life.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please share your closing thoughts about COPD management and outlook for the future.
Advertisement
Related to this article
Participants described earlier phenotyping, closer tracking of steroid exposure, and recognizing gradual gains on biologic therapy.
Participants described how payer requirements and documentation of steroid exposure shape biologic access.
At CHEST 2026, Retno Ariza Soemarwoto, MD, discusses curcumin’s effect on IL-17 in COPD, bioavailability, and what a guideline-ready trial needs.
Day 2 highlights from Phoenix covering PE intervention trials, pulmonary hypertension diagnostics, ILD telomere biology, and more.
Clinicians described how steroid exposure from multiple prescribers shapes biologic decisions in asthma and COPD.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, review early MiniMed Vivera data on optional meal announcements and twiist's new type 2 diabetes clearance.
Real-world data in 1477 patients on dialysis show tenapanor reduced serum phosphate at 6 months with or without background phosphate binders.
Approval rests on the phase 3 AFFIRM trial, in which 56% of patients reached clinical remission at week 12 vs 30% with placebo.
Advertisement
Advertisement
Trending on HCPLive
1
Retatrutide Lowers Albuminuria, Glomerular Pressure in Obesity and CKD
2
Sleeve Gastrectomy Improves Heart, Kidney MRI Markers in Youth-Onset T2D
3
TELIGAN: Telitacicept Preserves eGFR Through 2 Years in IgA Nephropathy
4
Ravulizumab Receives FDA Accelerated Approval for IgA Nephropathy
5